Pathology: mML - NA - all population; mML - NA - PDL1 positive;
mML - NA - all population | mML - NA - PDL1 positive | ||||||||||
E1609 (ipi10), 2020 | EORTC 18071, 2015 | E1609 (ipi3), 2020 | CheckMate 238, 2017 | IMMUNED (N vs P ; all population), 2020 | CheckMate 915, 0 | IMMUNED (NI vs N) EXPLORATORY, 2020 | IMMUNED (NI vs P ; all population), 2020 | KEYNOTE 054 (all population), 2018 | KEYNOTE 054 (PDL1>1%), 2018 | ||
nivolumab plus ipilimumab | 3 | T1 | T1 | T1 | |||||||
nivolumab alone | 2 | T1 | T1 | T0 | T0 | ||||||
pembrolizumab alone | 2 | T1 | T1 | ||||||||
Ipilimumab (10 mg/kg) | 2 | T1 | T1 | T0 | |||||||
ipilimumab alone | 1 | T1 | |||||||||
interferon alpha | 0 | T0 | T0 | ||||||||
placebo | 0 | T0 | T0 | T0 | T0 | T0 |